MetLife is a leading global provider of insurance, employee benefits, and asset management services. The company offers a wide range of products including life insurance, annuities, dental insurance, and retirement plans, catering to individuals and corporations alike. With a strong emphasis on financial security, MetLife aims to help its clients manage their risks and achieve their financial goals through innovative solutions and personalized services. The firm operates in multiple markets around the world, leveraging its extensive network and expertise to deliver quality service and support to its diverse customer base. Read More
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
MetLife has introduced a new Cancer Support benefit to help employees with personalized advice and attention from diagnosis to treatment and through recovery. Through a strategic relationship with Private Health Management, a leader in complex care navigation, MetLife will expand its Critical Illness Insurance offering to provide a more robust cancer benefit, including access to top oncology specialists, tech-enabled and expert-led coordination, and patient counseling – all of which help to provide a clearer path forward for patients. This announcement comes as new cases of cancer are anticipated to rise to more than two million in 2025.1
The U.S. stock market is navigating a turbulent start to September 2025, with major indexes experiencing notable declines after a strong August rally. This early-month pullback is being attributed to a confluence of factors, including rising bond yields, persistent inflation concerns, escalating geopolitical tensions, and the historically recognized "September
MetLife, Inc. (NYSE: MET) today announced that it will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share ("Series G Preferred Stock"), at a redemption price of $1,000 per share of Series G Preferred Stock. All outstanding shares of Series G Preferred Stock will be redeemed on the dividend payment date of September 15, 2025.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at MetLife (NYSE:MET) and its peers.
MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that it has named Geert Henckens global head of Private Fixed Income.
Are you a die-hard New York Giants fan looking to catch a thrilling game at MetLife Stadium without breaking the bank? Look no further! At CapitalCityTickets.com, you can score affordable New York Giants tickets and parking passes, saving even more with the exclusive promo code CITY10. This guide will walk you through how to snag the best deals on Giants tickets and parking for an unforgettable game-day experience in 2025.
Washington D.C. – Hopes for an imminent Federal Reserve interest rate cut have significantly dimmed following the release of hotter-than-expected Producer Price Index (PPI) data on August 14, 2025. The July PPI report revealed a surprising surge in wholesale inflation, forcing traders and economists to reconsider the widespread expectation of
MetLife, Inc. (NYSE: MET) today announced that Michel Khalaf, president and chief executive officer, and John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, will participate in a fireside chat at the 2025 Keefe, Bruyette & Woods Annual Insurance Conference on Wednesday, Sept. 3, 2025, from 10:05 a.m. to 10:45 a.m. (ET).
MetLife’s second quarter was marked by a 2.9% negative market reaction, reflecting investor concerns over results that fell short of Wall Street expectations. Management cited less favorable underwriting, especially in Group Benefits, and lower variable investment income as primary headwinds. CEO Michel Khalaf described the underwriting experience as “within normal fluctuations,” but acknowledged challenges in both life and non-medical health, while also noting strong momentum in Asia and Latin America. The quarter was further impacted by a handful of large disability claims, which management downplayed as non-recurring.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Global insurance giant MetLife (NYSE:MET) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $17.92 billion. Its non-GAAP profit of $2.02 per share was 6.3% below analysts’ consensus estimates.
Insurance and annuity provider Brighthouse Financial (NASDAQ:BHF) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 2.9% year on year to $2.15 billion. Its non-GAAP profit of $3.43 per share was 21.8% below analysts’ consensus estimates.
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.
Global insurance giant MetLife (NYSE:MET) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 7.2% year on year to $17.34 billion. Its non-GAAP profit of $2.02 per share was 6.3% below analysts’ consensus estimates.
